I, which it has previously said is slated for 2017. Switzerland -based gene-editing biotech firm CRISPR Therapeutics has filed with CRISPR Therapeutics to list its IPO on the Nasdaq with a view to raising $90m in the public arena, having already raised one in private funding. The company booked around $2m in sales for the year to end June , but posted operating losses of close to $30m in H1 2016 . Bayer (Casebia Therapeutics 's move follows other listings of notable biotech start-ups, Bayer (Casebia Therapeutics and Intellia . The firm already operates a joint venture with Switzerland ’s Bayer (Casebia Therapeutics ) and is working in collaboration with Vertex Pharmaceuticals on haemoglobin-related programmes.
Switzerland -based gene-editing biotech firm CRISPR Therapeutics has filed with CRISPR Therapeutics to list its IPO on the Nasdaq with a view to raising $90m in the public arena, having already raised one in private funding. The company booked around $2m in sales for the year to end June , but posted operating losses of close to $30m in H1 2016 . Bayer (Casebia Therapeutics 's move follows other listings of notable biotech start-ups, Bayer (Casebia Therapeutics and Intellia . The firm already operates a joint venture with Switzerland ’s Bayer (Casebia Therapeutics ) and is working in collaboration with Vertex Pharmaceuticals on haemoglobin-related programmes.